Loading...
Median survival in patients treated for metastatic colorectal cancer (mCRC) now exceeds 2 years. With well-defined first, second, and later lines of therapy, standard practice is to continue treatment until disease progression. Offering treatment breaks to patients with responding or stable disease is considered in clinical practice, but limited trial data are available to indicate the optimal strategy.
Investigators for the Dutch Colorectal Cancer Group now report results of the randomized, controlled, phase III CAIRO3 trial, which evaluated a maintenance chemotherapy strategy versus observation in 558 mCRC patients achieving either a response or stable disease after induction chemotherapy with capecitabine, oxaliplatin, and bevacizumab (CA…